BACKGROUND: @entity2449 , widely used in the treatment of @entity6 , reduces the risk of @entity5 and relapse after treatment. Fertility-sparing treatment for @entity1204 ( @entity1204 ) with @entity1871 is associated with a high chance of disease regression, and the high relapse rate continues to be a problem. We assessed the efficacy of @entity2449 in preventing recurrence after @entity11796 ( @entity3443 ) as fertility-sparing treatment for @entity1869 ( @entity1869 ) and @entity1204 . @entity1 AND METHODS: This phase II study enrolled 17 @entity1 with @entity1869 and 19 @entity1 with @entity1204 limited to the endometrium (age, 20-40 years). @entity3443 (400 mg/day) and @entity2449 (750-2250 mg/day) were administered for 24-36 weeks to achieve a complete response (CR). @entity2449 was administered until conception, even after @entity3443 discontinuation. The primary end point was @entity4557 ( @entity4557 ) after remission. We analyzed all efficacy end points in the full analysis set. RESULTS: The body mass index was >= 25 kg/m(2) in 27 @entity1 (mean, 31 kg/m(2); range, 19-51 kg/m(2)), and the homeostasis model assessment for insulin resistance index was >= 2.5 in 24 @entity1 (mean, 4.7; range, 0.7-21). Two @entity1 showed progression at 12 weeks [6%; 95% confidence interval (CI) 2-18]. At 36 weeks, 29 (81%; 95% CI 65-90) @entity1 achieved CR, and 5 (14%; 95% CI 6-29) @entity1 achieved partial response. During a median follow-up of 38 months (range, 9-66 months) after remission, relapse was confirmed in three of the @entity1 who had achieved CR (relapse rate, 10%). The 3-year estimated @entity4557 rate was 89%. No @entity1 experienced severe @entity137 . CONCLUSIONS: @entity2449 inhibited disease relapse after @entity3443 therapy. The combination of @entity2449 and @entity3443 in @entity1204 treatment should be studied further. TRIAL REGISTRATION NUMBER: UMIN 000002210.

Phase II study of @entity11796 plus XXXX as a fertility-sparing treatment for @entity1204   .

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer', 'EC'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus'] @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3443 :: ('D015097', 'Chemical') :: ['MPA'] @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['progestin'] @entity1869 :: ('MESH:D004714', 'Disease') :: ['atypical endometrial hyperplasia', 'AEH'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin']
@entity2449 :: (MESH:D008687,Chemical) :: ['metformin']
